CMS makes ocular surface anesthesia more accessible

CMS has issued a product-specific code for Harrow’s new ocular surface anesthesia Iheezo, enabling a more efficient billing process for healthcare providers. 

Advertisement

Iheezo, a topical anesthetic approved by the FDA in Sept. 2022, is the first ocular anesthetic approved for use in 14 years, according to a Feb. 2 press release. 

Iheezo does not require patients to receive any supplemental anesthesia to undergo surgical procedures. 

By receiving a product-specific CMS code, ophthalmologists, optometrists and retina specialists will be able to easily bill for Iheezo, creating greater accessibility for the product. 

Advertisement

Next Up in Ophthalmology

  • Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

  • Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

  • The American Board of Ophthalmology has appointed Steven Gedde, MD, as its next CEO.  Dr. Gedde is an ophthalmologist and…

Advertisement

Comments are closed.